2021 World Conference on Lung Cancer (WCLC) Highlights-WCLC Highlights Slides

WCLC Highlights Slides

Pdf Summary

The World Conference on Lung Cancer 2021 presented findings from several studies related to lung cancer care. One study focused on disparities in lung cancer care and emphasized the need for proactive interventions to address these disparities. Another study examined the impact of the COVID-19 pandemic on international lung cancer clinical trials, highlighting the challenges faced by trial sites and the strategies used to mitigate them. A separate study investigated the use of proton therapy for non-small cell lung cancer and its potential benefits in reducing normal tissue exposure. <br /><br />The study on disparities in lung cancer care emphasized the importance of social policy interventions in addressing healthcare disparities. The study revealed predictable patterns of disparities that emerge or worsen with discovery and innovation, emphasizing the need for active interventions to overcome them. <br /><br />The study on the impact of COVID-19 on international lung cancer clinical trials found that the pandemic created barriers to trial enrollment and completion. However, trial sites utilized various strategies such as telehealth visits and altered trial schedules to improve enrollment despite the challenges posed by the pandemic. <br /><br />The study on proton therapy for non-small cell lung cancer compared its outcomes with photon therapy. The study found that proton therapy was not associated with a reduced risk of death from intercurrent disease compared to photon therapy. <br /><br />Overall, the World Conference on Lung Cancer 2021 provided valuable insights into lung cancer care disparities, the impact of COVID-19 on clinical trials, and the potential benefits of proton therapy in non-small cell lung cancer. These findings can inform future efforts to improve lung cancer care and management.

Keywords

World Conference on Lung Cancer 2021

lung cancer care disparities

proactive interventions

COVID-19 pandemic

international lung cancer clinical trials

trial enrollment

telehealth visits

altered trial schedules

proton therapy

non-small cell lung cancer